Gabapentin Tablet, Film Coated
Product Images NDC 71335-2701

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2701). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

Creatinine Clearance (Gabapentin Fig1)
This text appears to be a formula for calculating creatinine levels in the blood based on age and weight for both male and female patients, with a different constant value for females. The formula involves multiplying the age in years by the weight in kilograms and then dividing by a constant value. This calculation can help in assessing kidney function.*
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)
This is a data visualization showing the Weekly Mean Pain Scores in a study comparing placebo and gabapentin at a dose of 300 mg/day. It illustrates the observed cases in the ITT Population over time.*
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)
Figure showing the difference from placebo in the efficacy of adjunctive therapy for individuals with partial seizures at 12 years of age. The graph displays the results at various daily doses ranging from 600 to 1800 mg.*
FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical Structure (Gabapentin Str)
FDA Label Image

Label (Lbl713352701)

Label (Lbl713352701)
The text provides information about Gabapentin tablets USP with a strength of 600 mg per film-coated tablet. It includes dosage instructions, storage conditions (20-25°C), and precautions (may cause dizziness, keep out of reach of children). The NDC for the tablets is 71335-2701-1, and they should be dispensed in a tight, child-resistant container. Further details can be found on the package insert or by scanning the QR code provided.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.